Ranbaxy Troubles Deepen As Apotex Seeks Declaratory Judgments On Valtrex, Aricept Exclusivity; Will Nexium and Lipitor Be Next?
This article was originally published in The Pink Sheet Daily
Executive Summary
Judgment on generic valacylovir would trigger Ranbaxy's 180-day exclusivity period even though Indian firm has yet to market its product because FDA is investigating its production facilities.
You may also be interested in...
U.S. FDA Nails Ranbaxy On Charges Of Falsifying Data; Halts All Application Reviews From Paonta Sahib Plant
MUMBAI - India's largest drug maker Ranbaxy received a body blow after the U.S. Food and Drug Administration initiated a new regulatory action against the company's Paonta Sahib-based manufacturing plant in India. The drug regulator halted review of drug applications from the manufacturing plant due to evidence of falsified data and invoked the Application Integrity Policy
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.